https://www.selleckchem.com/pr....oducts/paeoniflorin.
1-year primary patency, freedom from TLR, and assisted primary patency were 40% (median patent time 256 days), 67% (median patent time 524 days), and 77%, respectively. Conclusion Stenting for central venous occlusions and stenoses in the hemodialysis patients is safe and durable treatment option. However, considering its off-label use and potential hazard including vessel rupture, stent migration, and stent fracture, the indication for BMS deployment should be conservative, and interventionist should be well acquainted with preven
Like
Comment
Share
